previous studies demonstrated that glycolysis, as metabolic reprogramming, contributed significantly to cholangiocarcinoma initiation and progression [43, 44] Glycolic pathways and enzymes, including pyruvate kinase M2 [45, 46], Aldolase A [47] and lactate dehydrogenase A [48], play a critical role in BTC and have been utilized as biomarkers to predict patients` outcomes. The gene discussed is LDHA; the disease is cholangiocarcinoma.